Cargando…
Rates of Antimicrobial Resistance in Helicobacter pylori Isolates From Clinical Trial Patients Across the US and Europe
Guidelines recommend that proton pump inhibitor-based triple regimens with clarithromycin not be used for Helicobacter pylori infection in areas where clarithromycin resistance is ≥15%, or in patients with prior macrolide use. Up-to-date information on local resistance patterns is limited, especiall...
Autores principales: | Mégraud, Francis, Graham, David Y., Howden, Colin W., Trevino, Ernest, Weissfeld, Alice, Hunt, Barbara, Smith, Neila, Leifke, Eckhard, Chey, William D. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Wolters Kluwer
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9889195/ https://www.ncbi.nlm.nih.gov/pubmed/36191284 http://dx.doi.org/10.14309/ajg.0000000000002045 |
Ejemplares similares
-
Brief communication: global temporal trends in the efficacy of clarithromycin-based regimens for the treatment of Helicobacter pylori infection
por: Moss, Steven F., et al.
Publicado: (2023) -
Dormant phages of Helicobacter pylori reveal distinct populations in Europe
por: Vale, F. F., et al.
Publicado: (2015) -
Helicobacter pylori Strains and Gastric MALT Lymphoma
por: Floch, Pauline, et al.
Publicado: (2017) -
Update on the Management of Helicobacter pylori Infection
por: Saleem, Nasir, et al.
Publicado: (2020) -
Pitfalls of Physician-Directed Treatment of Helicobacter pylori: Results from Two Phase 3 Clinical Trials and Real-World Prescribing Data
por: Howden, Colin W., et al.
Publicado: (2021)